359 related articles for article (PubMed ID: 32394316)
1. Delivery of RNAi-Based Therapeutics for Bone Regeneration.
Malcolm DW; Wang Y; Overby C; Newman M; Benoit DSW
Curr Osteoporos Rep; 2020 Jun; 18(3):312-324. PubMed ID: 32394316
[TBL] [Abstract][Full Text] [Related]
2. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
3. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
4. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of small RNA using lipid nanoparticles.
Asai T; Oku N
Biol Pharm Bull; 2014; 37(2):201-5. PubMed ID: 24492716
[TBL] [Abstract][Full Text] [Related]
6. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
7. The current state and future directions of RNAi-based therapeutics.
Setten RL; Rossi JJ; Han SP
Nat Rev Drug Discov; 2019 Jun; 18(6):421-446. PubMed ID: 30846871
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
9. RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA.
Leng Q; Chen L; Lv Y
Theranostics; 2020; 10(7):3190-3205. PubMed ID: 32194862
[TBL] [Abstract][Full Text] [Related]
10. Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing.
Wang Y; Malcolm DW; Benoit DSW
Biomaterials; 2017 Sep; 139():127-138. PubMed ID: 28601703
[TBL] [Abstract][Full Text] [Related]
11. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
Kim B; Park JH; Sailor MJ
Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
[TBL] [Abstract][Full Text] [Related]
12. RNA interference and cancer therapy.
Wang Z; Rao DD; Senzer N; Nemunaitis J
Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588
[TBL] [Abstract][Full Text] [Related]
13. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
Scherman D; Rousseau A; Bigey P; Escriou V
Gene Ther; 2017 Mar; 24(3):151-156. PubMed ID: 28121307
[TBL] [Abstract][Full Text] [Related]
14. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
15. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
16. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
[TBL] [Abstract][Full Text] [Related]
18. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
[TBL] [Abstract][Full Text] [Related]
19. RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy.
Yoon J; Shin M; Lee JY; Lee SN; Choi JH; Choi JW
J Control Release; 2022 Feb; 342():228-240. PubMed ID: 35016917
[TBL] [Abstract][Full Text] [Related]
20. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
Barata P; Sood AK; Hong DS
Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
